PRECISION BIOSCIENCES INC

# Signal Note: Driehaus Capital Initiates DTIL Position Driehaus' $3.3M entry into Precision Biosciences signals conviction in the company's in vivo CRISPR pipeline, particularly **PBGM01 for sickle cell disease**, which is advancing toward clinical readout. The position timing may reflect confidence in upcoming data catalysts and the therapeutic potential of in vivo gene editing as a differentiated approach versus ex vivo competitors like CRISPR Therapeutics and Editas—though execution risk remains high given the nascent stage of the technology.